4D Molecular Therapeutics (FDMT) Stock Forecast, Price Target & Predictions
FDMT Stock Forecast
4D Molecular Therapeutics stock forecast is as follows: an average price target of $44.57 (represents a 174.28% upside from FDMT’s last price of $16.25) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
FDMT Price Target
The average price target for 4D Molecular Therapeutics (FDMT) is $44.57 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $63.00 to $30.00. This represents a potential 174.28% upside from FDMT's last price of $16.25.
FDMT Analyst Ratings
According to 4 Wall Street analysts, 4D Molecular Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for FDMT stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
4D Molecular Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 15, 2024 | Lisa Walter | RBC Capital | $40.00 | $26.35 | 51.80% | 146.15% |
| Apr 15, 2024 | Gena Wang | Barclays | $45.00 | $26.35 | 70.78% | 176.92% |
| Apr 01, 2024 | Nalin Tejavibulya | Jefferies | $58.00 | $31.86 | 82.05% | 256.92% |
| Mar 28, 2024 | Kostas Biliouris | BMO Capital | $63.00 | $31.59 | 99.43% | 287.69% |
| Feb 06, 2024 | Kostas Biliouris | BMO Capital | $70.00 | $30.70 | 127.98% | 330.77% |
| Jul 05, 2023 | Geulah Livshits | Chardan Capital | $30.00 | $18.43 | 62.78% | 84.62% |
| Nov 18, 2022 | - | H.C. Wainwright | $36.00 | $22.40 | 60.71% | 121.54% |
| Apr 05, 2022 | Josh Schimmer | Evercore ISI | $40.00 | $14.66 | 172.85% | 146.15% |
The latest 4D Molecular Therapeutics stock forecast, released on Apr 15, 2024 by Lisa Walter from RBC Capital, set a price target of $40.00, which represents a 51.80% increase from the stock price at the time of the forecast ($26.35), and a 146.15% increase from FDMT last price ($16.25).
4D Molecular Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 5 |
| Avg Price Target | - | - | $55.20 |
| Last Closing Price | $16.25 | $16.25 | $16.25 |
| Upside/Downside | -100.00% | -100.00% | 239.69% |
In the current month, the average price target of 4D Molecular Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to 4D Molecular Therapeutics's last price of $16.25. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 09, 2024 | Chardan Capital | Underperform | Underperform | Hold |
| Sep 09, 2024 | RBC Capital | Buy | Buy | Hold |
| Jul 22, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Jul 18, 2024 | RBC Capital | Buy | Buy | Hold |
| Jun 07, 2024 | RBC Capital | Buy | Buy | Hold |
| Jun 07, 2024 | Jefferies | Underperform | Underperform | Hold |
| Jun 07, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Apr 15, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Apr 15, 2024 | Barclays | - | Overweight | Initialise |
| Apr 01, 2024 | Jefferies | Buy | Buy | Hold |
4D Molecular Therapeutics's last stock rating was published by Chardan Capital on Sep 09, 2024. The company gave FDMT a "Underperform" rating, the same as its previous rate.
4D Molecular Therapeutics Financial Forecast
4D Molecular Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $-20.74M | $20.20M | $239.00K | $298.00K | $1.25M | $500.00K | - | $1.22M | $92.00K | $1.37M | $14.58M | $2.00M |
| Avg Forecast | $500.00K | $500.00K | $252.50K | $264.00K | $3.58M | $1.62M | $1.27M | $1.45M | $8.07M | $848.33K | $1.28M | $873.40K | $873.40K | $856.00K | $758.33K | $758.33K | $900.00K | $175.00K | $587.50K | $562.50K |
| High Forecast | $500.00K | $500.00K | $252.50K | $264.00K | $3.58M | $4.20M | $1.27M | $1.45M | $21.25M | $848.33K | $1.28M | $873.40K | $873.40K | $856.00K | $758.33K | $1.73M | $2.05M | $398.27K | $1.34M | $1.28M |
| Low Forecast | $500.00K | $500.00K | $252.50K | $264.00K | $3.58M | $12.73K | $1.27M | $1.45M | $345.48K | $848.33K | $1.28M | $873.40K | $873.40K | $856.00K | $758.33K | $261.49K | $310.34K | $60.34K | $202.59K | $193.97K |
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | 1 | 2 | 2 | 2 | 2 |
| Surprise % | - | - | - | - | - | - | - | - | -2.57% | 23.82% | 0.19% | 0.34% | 1.43% | 0.58% | - | 1.61% | 0.10% | 7.81% | 24.82% | 3.56% |
4D Molecular Therapeutics's average Quarter revenue forecast for Mar 24 based on 4 analysts is $1.45M, with a low forecast of $1.45M, and a high forecast of $1.45M. FDMT's average Quarter revenue forecast represents a -106.99% decrease compared to the company's last Quarter revenue of $-20.74M (Dec 23).
4D Molecular Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | 1 | 2 | 2 | 2 | 2 |
| EBITDA | - | - | - | - | - | - | - | - | $-29.80M | $-12.58M | $-32.14M | $-30.11M | $-27.33M | $-25.62M | - | $-25.61M | $-23.20M | $-21.86M | $-7.22M | $-16.02M |
| Avg Forecast | $-500.00K | $-500.00K | $-252.50K | $-264.00K | $-3.58M | $-1.62M | $-1.27M | $-1.45M | $-8.07M | $-848.33K | $-1.28M | $-873.40K | $-873.40K | $-20.68M | $-758.33K | $-25.24M | $-900.00K | $-22.12M | $-10.43M | $-20.85M |
| High Forecast | $-500.00K | $-500.00K | $-252.50K | $-264.00K | $-3.58M | $-12.73K | $-1.27M | $-1.45M | $-345.48K | $-848.33K | $-1.28M | $-873.40K | $-873.40K | $-16.55M | $-758.33K | $-20.19M | $-310.34K | $-17.70M | $-8.35M | $-16.68M |
| Low Forecast | $-500.00K | $-500.00K | $-252.50K | $-264.00K | $-3.58M | $-4.20M | $-1.27M | $-1.45M | $-21.25M | $-848.33K | $-1.28M | $-873.40K | $-873.40K | $-24.82M | $-758.33K | $-30.29M | $-2.05M | $-26.54M | $-12.52M | $-25.02M |
| Surprise % | - | - | - | - | - | - | - | - | 3.69% | 14.83% | 25.01% | 34.47% | 31.29% | 1.24% | - | 1.01% | 25.77% | 0.99% | 0.69% | 0.77% |
undefined analysts predict FDMT's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than 4D Molecular Therapeutics's previous annual EBITDA (undefined) of $NaN.
4D Molecular Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | 1 | 2 | 2 | 2 | 2 |
| Net Income | - | - | - | - | - | - | - | - | $-33.71M | $-10.26M | $-29.62M | $-27.26M | $-27.27M | $-24.09M | - | $-26.18M | $-25.08M | $-22.24M | $-7.59M | $-16.41M |
| Avg Forecast | $-54.18M | $-50.86M | $-51.97M | $-48.10M | $-41.49M | $-36.85M | $-37.82M | $-40.96M | $-33.90M | $-43.33M | $-49.39M | $-43.44M | $-43.44M | $-21.04M | $-40.03M | $-26.01M | $-33.26B | $-22.51M | $-10.97M | $-21.34M |
| High Forecast | $-54.18M | $-50.86M | $-51.97M | $-48.10M | $-41.49M | $-34.65M | $-37.82M | $-40.96M | $-19.44M | $-43.33M | $-49.39M | $-43.44M | $-43.44M | $-16.84M | $-40.03M | $-20.81M | $-4.93B | $-18.01M | $-8.77M | $-17.07M |
| Low Forecast | $-54.18M | $-50.86M | $-51.97M | $-48.10M | $-41.49M | $-38.50M | $-37.82M | $-40.96M | $-40.88M | $-43.33M | $-49.39M | $-43.44M | $-43.44M | $-25.25M | $-40.03M | $-31.22M | $-88.43B | $-27.01M | $-13.16M | $-25.61M |
| Surprise % | - | - | - | - | - | - | - | - | 0.99% | 0.24% | 0.60% | 0.63% | 0.63% | 1.14% | - | 1.01% | 0.00% | 0.99% | 0.69% | 0.77% |
4D Molecular Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. FDMT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
4D Molecular Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | 1 | 2 | 2 | 2 | 2 |
| SG&A | - | - | - | - | - | - | - | - | $10.60M | $9.11M | $8.79M | $7.99M | $8.47M | $8.05M | - | $8.23M | $7.33M | $8.19M | $6.95M | $5.54M |
| Avg Forecast | $1.68M | $1.68M | $848.85K | $887.51K | $12.05M | $5.44M | $4.26M | $4.87M | $27.12M | $2.85M | $4.32M | $2.94M | $2.94M | $2.88M | $2.55M | $2.55M | $3.03M | $588.31K | $1.98M | $1.89M |
| High Forecast | $1.68M | $1.68M | $848.85K | $887.51K | $12.05M | $14.13M | $4.26M | $4.87M | $71.43M | $2.85M | $4.32M | $2.94M | $2.94M | $2.88M | $2.55M | $5.80M | $6.89M | $1.34M | $4.49M | $4.30M |
| Low Forecast | $1.68M | $1.68M | $848.85K | $887.51K | $12.05M | $42.80K | $4.26M | $4.87M | $1.16M | $2.85M | $4.32M | $2.94M | $2.94M | $2.88M | $2.55M | $879.09K | $1.04M | $202.86K | $681.05K | $652.07K |
| Surprise % | - | - | - | - | - | - | - | - | 0.39% | 3.20% | 2.03% | 2.72% | 2.88% | 2.80% | - | 3.23% | 2.42% | 13.92% | 3.52% | 2.93% |
4D Molecular Therapeutics's average Quarter SG&A projection for Mar 24 is $4.87M, based on 4 Wall Street analysts, with a range of $4.87M to $4.87M. The forecast indicates a -54.05% fall compared to FDMT last annual SG&A of $10.60M (Dec 23).
4D Molecular Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | 1 | 2 | 2 | 2 | 2 |
| EPS | - | - | - | - | - | - | - | - | $-0.00 | $-0.24 | $-0.77 | $-0.83 | $-0.84 | $-0.74 | - | $-0.81 | $-0.93 | $-0.82 | $-0.28 | $-0.61 |
| Avg Forecast | $-0.98 | $-0.92 | $-0.94 | $-0.87 | $-0.75 | $-0.67 | $-0.68 | $-0.74 | $-0.61 | $-0.78 | $-0.89 | $-0.79 | $-0.79 | $-0.85 | $-0.81 | $-0.81 | $-0.85 | $-0.81 | $-0.68 | $-0.83 |
| High Forecast | $-0.98 | $-0.92 | $-0.94 | $-0.87 | $-0.75 | $-0.63 | $-0.68 | $-0.74 | $-0.35 | $-0.78 | $-0.89 | $-0.79 | $-0.79 | $-0.85 | $-0.81 | $-0.12 | $-0.13 | $-0.12 | $-0.10 | $-0.12 |
| Low Forecast | $-0.98 | $-0.92 | $-0.94 | $-0.87 | $-0.75 | $-0.70 | $-0.68 | $-0.74 | $-0.74 | $-0.78 | $-0.89 | $-0.79 | $-0.79 | $-0.85 | $-0.81 | $-2.16 | $-2.26 | $-2.15 | $-1.81 | $-2.21 |
| Surprise % | - | - | - | - | - | - | - | - | 0.00% | 0.31% | 0.86% | 1.06% | 1.07% | 0.87% | - | 1.00% | 1.09% | 1.01% | 0.41% | 0.73% |
According to undefined Wall Street analysts, 4D Molecular Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to FDMT previous annual EPS of $NaN (undefined).
4D Molecular Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| BCEL | Atreca | $0.09 | $4.00 | 4344.44% | Buy |
| IPSC | Century Therapeutics | $1.60 | $20.00 | 1150.00% | Buy |
| KRON | Kronos Bio | $0.95 | $7.63 | 703.16% | Buy |
| PASG | Passage Bio | $0.81 | $6.00 | 640.74% | Buy |
| GOSS | Gossamer Bio | $0.92 | $3.75 | 307.61% | Buy |
| FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
| FDMT | 4D Molecular Therapeutics | $16.25 | $44.57 | 174.28% | Buy |
| MLYS | Mineralys Therapeutics | $11.76 | $30.00 | 155.10% | Buy |
| EWTX | Edgewise Therapeutics | $18.83 | $48.00 | 154.91% | Buy |
| BDTX | Black Diamond Therapeutics | $6.19 | $14.75 | 138.29% | Buy |
| STOK | Stoke Therapeutics | $14.47 | $33.75 | 133.24% | Buy |
| REPL | Replimune Group | $11.13 | $24.20 | 117.43% | Buy |
| LYRA | Lyra Therapeutics | $0.28 | $0.50 | 78.57% | Hold |
| CGEM | Cullinan Oncology | $17.95 | $32.00 | 78.27% | Buy |
| CCCC | C4 Therapeutics | $6.44 | $11.33 | 75.93% | Hold |
| BMEA | Biomea Fusion | $7.85 | $13.67 | 74.14% | Buy |
| AKRO | Akero Therapeutics | $27.34 | $43.50 | 59.11% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $43.70 | $51.20 | 17.16% | Buy |
FDMT Forecast FAQ
Is 4D Molecular Therapeutics a good buy?
Yes, according to 4 Wall Street analysts, 4D Molecular Therapeutics (FDMT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of FDMT's total ratings.
What is FDMT's price target?
4D Molecular Therapeutics (FDMT) average price target is $44.57 with a range of $30 to $63, implying a 174.28% from its last price of $16.25. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will 4D Molecular Therapeutics stock go up soon?
According to Wall Street analysts' prediction for FDMT stock, the company can go up by 174.28% (from the last price of $16.25 to the average price target of $44.57), up by 287.69% based on the highest stock price target, and up by 84.62% based on the lowest stock price target.
Can 4D Molecular Therapeutics stock reach $20?
FDMT's average twelve months analyst stock price target of $44.57 supports the claim that 4D Molecular Therapeutics can reach $20 in the near future.
What are 4D Molecular Therapeutics's analysts' financial forecasts?
4D Molecular Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $7.92M (high $10.5M, low $6.31M), average EBITDA is $-7.916M (high $-6.312M, low $-10.501M), average net income is $-157M (high $-155M, low $-159M), average SG&A $26.61M (high $35.3M, low $21.22M), and average EPS is $-2.842 (high $-2.802, low $-2.872). FDMT's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1.52M (high $1.52M, low $1.52M), average EBITDA is $-1.516M (high $-1.516M, low $-1.516M), average net income is $-205M (high $-205M, low $-205M), average SG&A $5.1M (high $5.1M, low $5.1M), and average EPS is $-3.71 (high $-3.71, low $-3.71).
Did the FDMT's actual financial results beat the analysts' financial forecasts?
Based on 4D Molecular Therapeutics's last annual report (Dec 2022), the company's revenue was $3.13M, which missed the average analysts forecast of $3.25M by -3.61%. Apple's EBITDA was $-110M, beating the average prediction of $-47.555M by 131.38%. The company's net income was $-101M, missing the average estimation of $-131M by -22.56%. Apple's SG&A was $32.91M, beating the average forecast of $10.91M by 201.56%. Lastly, the company's EPS was $-3.12, missing the average prediction of $-3.257 by -4.20%. In terms of the last quarterly report (Dec 2023), 4D Molecular Therapeutics's revenue was $-20.741M, missing the average analysts' forecast of $8.07M by -357.11%. The company's EBITDA was $-29.803M, beating the average prediction of $-8.067M by 269.45%. 4D Molecular Therapeutics's net income was $-33.707M, missing the average estimation of $-33.902M by -0.58%. The company's SG&A was $10.6M, missing the average forecast of $27.12M by -60.92%. Lastly, the company's EPS was $-0.0009, missing the average prediction of $-0.613 by -99.85%